Table of Contents Table of Contents
Previous Page  526 / 812 Next Page
Information
Show Menu
Previous Page 526 / 812 Next Page
Page Background

S522

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

EV539

Plasma concentrations of

endocannabinoids and congeners in a

primary care sample of depressed

patients: Influence of biological

variables, severity and antidepressant

medication

P. Romero-Sanchiz

1 ,

, R. Nogueira-Arjona

2

, F. Mayoral-Cleríes

1

,

F. Rivas-Guerrero

1

, P. Araos-Gómez

3

, M. Pedraz-Fernández

3

,

A. Serrano-Criado

3

, F.J. Pavón-Morón

3

, R. De la Torre-Fornell

4

,

A. Pastor-Bosch

4

, F. Rodríguez de Fonseca

3

1

IBIMA – Hospital Regional Universitary Malaga, Mental Health,

Málaga, Spain

2

IBIMA – University of Malaga, Personality – assessment and

psychological treatment, Málaga, Spain

3

IBIMA, Neropsychopharmacology, Malaga, Spain

4

IMIM, Integrated Pharmacology and Systems Neurosciences,

Barcelona, Spain

Corresponding author.

Introduction

Endocannabinoid system has been highlighted as

one of the most relevant research topics by neurobiologists, phar-

macists, basic scientists and clinicians. The association between

endocannabinoids and its congeners and mood disorders is rela-

tively recent. However, evidence from both clinical and preclinical

studies is increasing and many researchers point out endocannabi-

noid system and particularly endocannabinoids and congeners as

promising pharmacological targets.

Aims and objectives

Themain objective of this study is to compare

the plasma concentrations of endocannabinoids and congeners

between a sample of patients with depression and a sample of con-

trol subjects, and the influence of variables such as age, body mass

index, gender, severity of symptoms, and antidepressant medica-

tion.

Method

Plasma concentrations of endocannabinoids and con-

geners will be analyzed in 69 patients with depression from

primary care and 47 controls using mass spectrometry analysis.

Results

Statistically significant

differences in 2-

arachidonoylglycerol and monoacylglycerols were found between

both samples. Somatic symptoms of depression seems to be more

related to these compounds that to cognitive-affective symptoms.

In addition, differences between mildly and moderately depressed

patients were found in concentrations of AEA, LEA, DGLEA and

POEA. Patients with antidepressant medication showed higher

levels of 2-AG, DGLEA and OEA.

Conclusions

The results of this study provide evidence support-

ing the hypothesis that in depression there is a dysregulation of the

inflammatory signaling and, consequently the immune system. The

results of this study could also support the realization of transla-

tional research to better understand the mechanisms of this widely

distributed system.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1524

EV540

Efficacy of lurasidone in major

depression with mixed features:

Pattern of improvement in depressive

and manic symptoms

A.A. Nierenberg

1 , J. T

sai

2 ,

, Y . M

ao

3 , A.

Pikalov

4 , T. S

uppes

5 ,

A. Loebel

4

1

Boston, USA

2

Sunovion Pharmaceuticals Inc., Medical Affairs, Marlborough, USA

3

Sunovion Pharmaceuticals Inc., Biostatisticsd, Fort Lee, USA

4

Sunovion Pharmaceuticals Inc., Medical Affairs, Fort Lee, USA

5

Stanford School of Medicine, Psychiatry and Behavioral Sciences,

Stanford, USA

Corresponding author.

Introduction

Evidence indicates that manic symptoms, below the

threshold for hypomania (mixed features), are common in individ-

uals with major depressive disorder (MDD).

Objectives/aims

To evaluate the effect of lurasidone on specific

depressive and manic symptoms, based on Montgomery Asberg

Depression Rating Scale (MADRS) and Young Mania Rating Scale

(YMRS) items, in patients with MDD with mixed features.

Methods

Patients meeting DSM-IV-TR criteria for MDD, who

presented with 2–3 protocol-specified manic symptoms, were ran-

domized to 6 weeks of double-blind treatment with lurasidone

monotherapy 20–60mg/d (

n

= 109) or placebo (

n

= 100). Change

from baseline in the MADRS total, MADRS-6 core depression sub-

scale, individual MADRS items, and total and individual items of

the YMRS were analyzed by MMRM, and Cohen’s

d

effect sizes (

d

)

were calculated for week 6 change scores.

Results

Lurasidone improved depressive symptoms at week 6

in the MADRS total score (–20.5 vs. –13.0;

P

< 0.0001;

d

= 0.8) and

MADRS-6 core depression score (–13.0 vs. –8.5;

P

< 0.0001;

d

= 0.7).

Significant improvement on lurasidone was observed at week 6 on

all ten MADRS items (

d

= 0.36–0.78). Effect sizes for the MADRS-

6 core depression subscale items ranged from 0.36 to 0.78 at

week 6. Treatment with lurasidone was associated with signifi-

cantly greater week 6 improvement on the YMRS (–7.0 vs. –4.9;

P

< 0.0001). Effect sizes for the 5 YMRS items with baseline item

severity

2 ranged from 0.32 to 0.48.

Conclusions

In this study of MDD with mixed features, lurasi-

done was effective in treating the range of depressive and manic

symptoms that patients presented with.

Sponsored by Sunovion Pharmaceuticals Inc.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1525

EV541

Effect of meta-cognitive therapy on

patients of depression: A case series

from India

V. Sharma

1 ,

, M. Mehta

2

, R. Sagar

2

1

New Delhi, India

2

All India Institute of Medical Sciences, Department of Psychiatry,

New Delhi, India

Corresponding author.

Background

Metacognitive Therapy (MCT) for depression aims

at targeting attentional control, rumination, worry, and metacog-

nitive beliefs of individuals.

Aim

The purpose of this study was to examine the effects of

meta-cognitive therapy (MCT) in the treatment of patients with

a diagnosis of major depressive disorder.

Methods

Five patients diagnosed as having major depressive

disorder were recruited for the study. Each patient received 10 ses-

sions of MCT up to 1 hour each at a frequency of once per week.

All patients were assessed at baseline, which was followed by 10

weekly sessions of MCT with post-intervention assessment and

follow-up assessments at 1-month post-treatment. Primary out-

come measures were the reduction in symptoms of depression,

worry, and rumination. Outcomes were assessed via self-report

using structured psychological tests.

Data analysis

Datawas analyzedusing individual frequency com-

parisons where measures of differences were obtained within

each phase of assessment. Pre-intervention, post-intervention and

follow-up measures were compared along with identification of

within phase differences. Meticulous analysis was also performed

using measures of qualitative analysis. For this purpose, following

measures were used: homework assignment analysis, within ses-